(Tromsø 07 November 2024) Michael Akoh, CEO has on 07 November purchased 7.660
shares in ArcticZymes Technologies ASA for NOK 13.26 per share. Following this
transaction holds Mr. Akoh 7.660 shares and 200.000 options in the company.

Sharon Brownlow,  Board member has on 7 November purchased 10.570 shares in
ArcticZymes Technoloiges ASA for GBP 0.9378 per share. Following this
transaction holds Mrs. Brownlow 10.570 shares in the company.

This information is subject to the disclosure requirements in articles 19 of the
Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the
Norwegian Securities Trading Act.

For additional information, please contact
Børge Sørvoll
CFO
+4795290187
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker.
Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.
ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com


